The ultra-functional potential of nickel oxide (NiO) and magnesium oxide (MgO) nanoparticles (NPs), provides for extensive attention in the use of these metal oxides as a remarkable and electroactive nanocomposite in potentiometric and sensing investigations. This work proposed a new strategy for quantifying doxorubicin hydrochloride (DOX) in pharmaceuticals and human plasma by preparing a NiO/MgO core-shell nanocomposite modified coated wire membrane sensor. Doxorubicin hydrochloride was incorporated with phosphomolybdic acid (PMA) to produce doxorubicin hydrochloride phosphomolybdate (DOX-PM) as an electroactive material in the presence of polymeric high molecular weight poly vinyl chloride (PVC) and solvent mediator o-nitrophenyloctyl ether (o-NPOE). The modified sensor exhibited ultra sensitivity and high selectivity for the detection and quantification of doxorubicin hydrochloride with a linear relationship in the range of 1.0 × 10-11-1.0 × 10-2 mol L-1. The equation of regression was estimated to be EmV = (57.86 ± 0.8) log [DOX] + 723.19. However, the conventional type DOX-PM showed a potential response over a concentration range of 1.0 × 10-6-1.0 × 10-2 mol L-1 and a regression equation of EmV = (52.92 ± 0.5) log [DOX] + 453.42. The suggested sensors were successfully used in the determination of doxorubicin hydrochloride in commercial injections and human plasma.
Keywords: commercial injections; doxorubicin hydrochloride; human plasma; metal oxide nanocomposites; modified sensors.